Get started
Author

Anshu Vashishtha

Observed names: A Vashishtha, A. Vashishtha
OpenAlex ID: A5113730080
Angiotensin-Converting–Enzyme Genotype and Ischemic Heart Disease
1995 · B R Meyer, A Vashishtha · New England Journal of Medicine · 17
Safety data and patterns of progression in met diagnostic subgroups in OAM4558g; A phase II trial evaluating MetMAb in combination with erlotinib in advanced NSCLC.
2011 · A. Vashishtha, P. H. Patel, et al. · Journal of Clinical Oncology · 8
GS-3583, a novel FLT3 agonist Fc fusion protein, to expand conventional dendritic cells in healthy volunteers.
2021 · Nishanthan Rajakumaraswamy, Anees Dauki, et al. · Journal of Clinical Oncology · 6
SAT0131 Long-Term Safety of Rituximab: Pooled Analysis of the Rheumatoid Arthritis Global Clinical Trial Programme Over 11 Years
2013 · R.F. van Vollenhoven, P. Emery, et al. · Annals of the Rheumatic Diseases · 3
380 GS-3583, a novel FLT3 agonist Fc fusion protein, expands conventional dendritic cells in healthy volunteers
2021 · Nishanthan Rajakumaraswamy, Anees Dauki, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
FRI0223 Long-term targeted safety event rates in ra patients following initiation of rituximab: interim analysis from sunstone registry
2013 · D. Furst, K.L. Winthrop, et al. · Annals of the Rheumatic Diseases · 2
Abstract B295: A Phase Ib study of bavituximab plus carboplatin and pemetrexed in chemotherapy-naïve incurable stage IIIb/IV non-squamous non-small cell lung cancer.
2013 · Juneko E. Grilley-Olson, Liza C. Villaruz, et al. · Molecular Cancer Therapeutics · 1
Actr-50. Marizomib (mrz) With Bevacizumab (bev) in Who Grade Iv Malignant Glioma (g4 Mg): Full Enrollment Results From the Phase 1, Multicenter, Open-label Study
2016 · Daniela Bota, Annick Desjardins, et al. · Neuro-Oncology
FRI0216 Effect of concomitant statins on rituximab efficacy in patients with ra
2013 · A. Vashishtha, P.B. Lehane, et al. · Annals of the Rheumatic Diseases
Works count: 9
Citation count: 39
H-index: 3
I10-index: 1
Year
Topic
Type